Table of Contents
Microfluidics Market Overview
Microfluidics is a multidisciplinary field focused on handling tiny fluid volumes, typically on a microliter to picoliter scale, with applications spanning from lab-on-a-chip devices for DNA analysis and diagnostics to drug delivery systems and environmental monitoring. Fabricated using methods like soft lithography, these devices often employ materials like silicone elastomers and glass.
Precise fluid control mechanisms are integral to their operation, including pressure-driven flow and electrokinetic methods. Despite challenges like clogging and cost-intensive fabrication, microfluidics holds promise in personalized medicine, drug discovery, and more, as ongoing research seeks to enhance sensitivity, automation, and integration with other technologies.
Market Drivers
The demand for miniaturization and automation in healthcare, pharmaceuticals, and environmental monitoring industries primarily drives the global microfluidics market. These technologies enable precise and efficient handling of small fluid volumes, making them attractive for medical diagnostics and drug development applications.
In particular, the biomedical and healthcare sectors have seen significant growth in microfluidics adoption, driven by the need for rapid diagnostics and point-of-care testing. Ongoing research and development efforts and the response to global health crises like COVID-19 further contribute to the market’s expansion. Additionally, emerging markets in regions like Asia-Pacific are playing a role in diversifying and driving market growth.
Market Size
The global microfluidics market was worth $18.1 billion in 2021, and it is expected to maintain a steady annual growth rate of 15.5%, leading to an estimated market size of $88.32 billion between 2023 and 2032.
List of Major Companies
These are the top ten companies operating in the Microfluidics Market:
- Bio-Rad-Laboratories
- Illumina
- PerkinElmer
- Abbott-Laboratories
- Thermo-Fisher-Scientific
- Biomerieux
- Qiagen
- Danaher
- Agilent-Technologies
- Sphere-Fluidics
Bio-Rad-Laboratories
Company Overview
| Establishment Year | 1952 |
| Headquarter | Hercules, California, US. |
| Key Management | Norman Schwartz (President & CEO) |
| Revenue (US$ Bn) | $ 2.9 Billion (2021) |
| Headcount | ~ 8,200 (2022) |
| Website | https://www.bio-rad.com/ |
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc. is a prominent global leader in microfluidics, renowned for its substantial contributions to life sciences research and clinical diagnostics. The company is actively engaged in developing and providing microfluidic solutions for various applications, including genomics and single-cell analysis.
Bio-Rad Laboratories has played a pivotal role in advancing microfluidic technology by offering innovative platforms and systems that enable precise manipulation and examination of small volumes of liquids, particularly in fields such as droplet digital PCR (ddPCR) and single-cell genomics. Their expertise and presence have left a notable imprint on the advancement of microfluidics in research and diagnostics.
Geographical Presence
Bio-Rad Laboratories, Inc. is a global company with a significant presence across North America, Europe, Asia-Pacific, Latin America, Africa, and the Middle East.
Headquartered in Hercules, California, Bio-Rad has established offices, manufacturing facilities, and distribution centers in key countries and regions, including the United States, Canada, the United Kingdom, Germany, France, China, Japan, Brazil, Mexico, and the United Arab Emirates.
Recent Developments
- In October 2023, Bio-Rad Laboratories expanded its line of monoclonal anti-idiotypic antibodies, introducing six for dupilumab (Dupixent) and adding antibodies for ipilimumab (Yervoy), evolocumab (Repatha) and secukinumab (Cosentyx).
- In September 2023, Bio-Rad Laboratories, Inc. unveiled the PTC Tempo 384 Thermal Cyclers and PTC Tempo 48/48, created to simplify PCR applications for process development, research, and quality control in fundamental and translational contexts.
Illumina
Company Overview
| Establishment Year | 1998 |
| Headquarter | San Diego, California, US. |
| Key Management | Jacob Thaysen (CEO) |
| Revenue (US$ Bn) | $ 4.5 B (2022) |
| Headcount | ~ 10,200 (2022) |
| Website | https://www.illumina.com/ |
About Illumina
Illumina, Inc. is a distinguished leader in genomics and genetic analysis, with a substantial presence in microfluidics. The company is renowned for its groundbreaking contributions to the development and use of microfluidic technologies in the context of DNA sequencing.
Illumina’s primary sequencing platforms, the HiSeq and NovaSeq systems, use microfluidic chips to enable swift and highly precise DNA sequencing, marking a transformative impact on genomics research and clinical diagnostics. Furthermore, Illumina actively participates in enhancing microfluidic-based procedures for DNA sample preparation, including library preparation.
Geographical Presence
Illumina has a global presence, headquartered in San Diego, California, with additional offices, manufacturing facilities, and distribution centers in the United States, Europe (including the United Kingdom, Germany, France, and Spain), the Asia-Pacific region (including China, Japan, Australia, and Singapore), Canada, and select collaborations in Latin America.
Recent Developments
- In November 2023, Illumina Inc. launched an improved distributed liquid biopsy test called TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2). This research assay enables a thorough genomic analysis of circulating tumor DNA (ctDNA) in blood samples, serving as a noninvasive alternative when tissue testing is unavailable or as a complement to tissue-based testing.
- In August 2023, Illumina Inc., a prominent player in array-based technologies and DNA sequencing shared the news of inaugurating a fresh office and an advanced Illumina Solutions Center in Bengaluru, India.
PerkinElmer
Company Overview
| Establishment Year | 1937 |
| Headquarter | Waltham, Massachusetts, United States |
| Key Management | Prahlad Singh (President and CEO) |
| Revenue (US$ Bn) | $ 5.0 Billion (2021) |
| Headcount | ~16,000 (2021) |
| Website | https://www.perkinelmer.com/analytical-and-enterprise-solutions.html |
About PerkinElmer
PerkinElmer Inc. is a globally recognized corporation known for its active involvement in the microfluidics domain. The company specializes in developing and providing microfluidic solutions, particularly in the realms of life sciences, diagnostics, and analytical instrumentation.
PerkinElmer’s microfluidic platforms and systems are designed to facilitate precise and efficient manipulation of small fluid volumes, making them vital tools in applications such as genomics, proteomics, drug discovery, and genetic analysis.
The company’s contributions extend to developing microfluidic-based technologies for tasks like DNA sequencing, genotyping, and digital PCR, playing a significant role in research and clinical laboratories.
Geographical Presence
PerkinElmer Inc. is a global company headquartered in Waltham, Massachusetts, USA, with a significant presence in North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
They operate offices, manufacturing facilities, and research centers in numerous countries, including the United States, Canada, the United Kingdom, France, Germany, China, Japan, Brazil, and Mexico.
Recent Development
- In March 2023, PerkinElmer finalized the division it had previously revealed in August with the sale of its applied science, food, and enterprise services divisions to New Mountain Capital, a private equity firm. Simultaneously, the company merged its remaining life sciences and diagnostics operations to establish a new, independent entity.
- In February 2023, PerkinElmer, Inc., a global leader dedicated to advancing global health, introduced the EnVision Nexus system, its latest and most responsive multimode plate reader for high-throughput screening (HTS) applications in drug discovery, aimed at speeding up the drug discovery process.
Abbott-Laboratories
Company Overview
| Establishment Year | 1888 |
| Headquarter | Illinois, US |
| Key Management | Robert B. Ford (Chairman & CEO) |
| Revenue (US$ Bn) | $43.7 Billion (2022) |
| Headcount | ~ 115,000 (2022) |
| Website | http://abbott.com/ |
About Abbott Laboratories
Abbott Laboratories, a prominent global healthcare company, has a notable presence in microfluidics, particularly in healthcare and diagnostics. The company specializes in developing and providing microfluidic-based diagnostic platforms and assays that enable precise and rapid analysis of biological samples, including handheld and portable devices for blood glucose monitoring, infectious disease detection, and cardiac biomarker analysis.
Abbott’s microfluidic technologies also play a vital role in molecular diagnostics, facilitating the detection of pathogens, genetic disorders, and various medical conditions.
Geographical Presence
Abbott has a strong presence in North America, particularly in the United States, where it is headquartered. In Europe, it maintains offices, manufacturing sites, and distribution centers in countries such as the United Kingdom, Germany, France, Italy, and Spain.
The company also has a substantial presence in Asia-Pacific, with operations in China, Japan, India, Australia, and South Korea. In addition, Abbott serves Latin America, the Middle East, Africa, Canada, and other regions, offering a diverse portfolio of healthcare products.
Recent Developments
- In November 2023, Abbott gained approval from the US Food and Drug Administration (FDA) for its molecular screening solution for human papillomavirus (HPV). This approval enhances the Alinity m family of diagnostic tests by introducing an effective tool for cancer screening, particularly for detecting high-risk HPV infections.
- In September 2023, Abbott acquired Bigfoot Biomedical, a prominent player in developing smart insulin management systems for individuals with diabetes. This acquisition strengthens Abbott’s position in diabetes care, complementing its leading FreeStyle Libre continuous glucose monitoring technology.
Thermo-Fisher-Scientific
Company Overview
| Establishment Year | 1956 |
| Headquarter | Waltham, Massachusetts, US |
| Key Management | Marc N. Casper (President & CEO) |
| Revenue (US$ Bn) | $44.9 Billion (2022) |
| Headcount | ~ 130,000 (2022) |
| Website | https://www.thermofisher.com/in/en/home.html |
About Thermo Fisher Scientific
Thermo Fisher Scientific is a globally renowned leader in scientific research and healthcare, with a notable presence in microfluidics. The company specializes in developing and providing microfluidic solutions, particularly in life sciences, diagnostics, and analytical instrumentation.
Thermo Fisher’s microfluidic platforms and systems are designed to precisely manipulate small fluid volumes, serving vital roles in genomics, proteomics, drug discovery, and diagnostics. Notably, in both research and clinical laboratories, the company’s microfluidic-based technologies are widely used for genetic analysis, including DNA sequencing, genotyping, and digital PCR.
Geographical Presence
Thermo Fisher Scientific is a global company headquartered in Waltham, Massachusetts, USA, with a widespread presence across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa. The company operates manufacturing facilities, research centers, and distribution hubs in these regions, catering to various industries, including life sciences, healthcare, and environmental services.
Recent Developments
- In November 2023, Thermo Fisher Scientific inaugurated its Battery Customer Experience Center in Seoul, South Korea. This state-of-the-art facility aims to aid battery manufacturers in developing innovative solutions aligned with the United Nations Sustainable Development Goal of ensuring everyone’s affordable, reliable, sustainable, and modern energy access by 2030.
- In September 2023, Thermo Fisher Scientific, a worldwide leader in scientific solutions, introduced the Thermo Scientific Meridian EX System. This innovative solution utilizes electron-beam technology and is designed to identify faults in advanced semiconductor logic technologies precisely.
Biomerieux
Company Overview
| Establishment Year | 1963 |
| Headquarter | Marcy-l’Étoile, France |
| Key Management | Pierre Boulud (CEO) |
| Revenue (US$ Bn) | $ 3.8 Billion (2022) |
| Headcount | ~ 13,842 (2022) |
| Website | https://www.biomerieux.com/ |
About BioMérieux
BioMérieux is a renowned global company specializing in diagnostics and microbiology, with a significant presence in microfluidics. The company actively develops and provides microfluidic solutions, particularly in clinical diagnostics and medical testing.
BioMérieux’s focus in microfluidics revolves around creating and applying microfluidic-based diagnostic platforms and assays, allowing precise manipulation of small biological sample volumes. Their contributions are notable in developing rapid diagnostic tests for infectious diseases, enabling swift and accurate results for timely clinical decision-making.
Geographical Presence
The company operates extensively across Europe, including the United Kingdom, Germany, Italy, and Spain. In North America, it has a substantial presence in the United States and Canada.
The Asia-Pacific region also features prominently in BioMérieux’s footprint, with operations in China, Japan, India, and Australia. The company also serves Latin America and the Middle East/Africa regions.
Recent Developments
- In October 2023, Oxford Nanopore Technologies plc and bioMérieux SA, a leading player in in vitro diagnostics (IVD), jointly announced that bioMérieux is investing £70 million in Oxford Nanopore with immediate effect.
- In October 2023, bioMérieux, a global leader in in vitro diagnostics, unveiled the CE-marking of VIDAS TBI (GFAP, UCH-L1), a blood test designed to aid in the evaluation of individuals with mild traumatic brain injury (mTBI). This test relies on a distinctive combination of brain biomarkers, specifically GFAP and UCH-L1*.
Qiagen
Company Overview
| Establishment Year | 1984 |
| Headquarter | Venlo, Netherlands |
| Key Management | Thierry Bernard (Chief Executive Officer) |
| Revenue (US$ Bn) | $ 2,251.7 Million (2021) |
| Headcount | ~ 6000 (2022) |
| Website | https://www.qiagen.com/us |
About Qiagen
Qiagen is a globally renowned company known for its expertise in molecular diagnostics, and it has a significant presence in the microfluidics field. The company actively engages in the development and provision of microfluidic solutions, particularly in the domains of molecular biology and diagnostics.
Qiagen’s primary focus in microfluidics revolves around creating and applying microfluidic-based technologies for sample preparation, which enables precise and efficient processing of biological materials such as DNA, RNA, and proteins.
Qiagen’s noteworthy contributions are evident in their innovative sample preparation kits and devices that leverage microfluidic technology to facilitate the extraction, purification, and handling of biomolecules with exceptional accuracy.
Geographical Presence
It maintains offices, manufacturing facilities, and distribution centers in North America, including the United States, Canada, and Mexico, while in Europe, its key locations include Germany, the Netherlands, France, Italy, Spain, and the United Kingdom.
Qiagen has expanded its reach in the Asia-Pacific region, with operations in China, Japan, India, Australia, and Singapore. It also has a presence in Latin America, including Brazil, Argentina, and Chile, as well as in the Middle East and Africa.
Recent Development
- In November 2023, Qiagen unveiled new kits suitable for utilization on its QIAcuity systems, accompanied by a significant software update to broaden the range of applications for digital PCR technology. These applications include cell and gene therapies, DNA and RNA quantification, and ensuring food and pharmaceutical safety.
- In November 2023, QIAGEN and Element Biosciences, Inc. disclosed a strategic collaboration to provide complete next-generation sequencing (NGS) processes for the AVITI System. This innovative sequencing platform utilizes Element’s unique Avidity sequencing chemistry.
Danaher
Company Overview
| Establishment Year | 1969 |
| Headquarter | Washington, DC, US. |
| Key Management | Steven Rales (Chairman of the Board) |
| Revenue (US$ Bn) | $ 31.4 Billion (2022) |
| Headcount | ~ 81,000 (2022) |
| Website | https://danaher.com/ |
About Danaher Corporation
Danaher Corporation, a renowned conglomerate, is significant in microfluidics, particularly within the life sciences and diagnostics sectors. The company actively develops and provides microfluidic-based solutions, facilitating the precise manipulation of small fluid volumes.
Danaher’s notable contributions to the microfluidics field encompass a portfolio of microfluidic instruments and systems vital for applications in genomics, proteomics, and various life sciences endeavors. These technologies are pivotal in DNA sequencing, cell analysis, and drug discovery.
Geographical Presence
Danaher Corporation, headquartered in Washington, DC, has a global presence in North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa. In North America, it has manufacturing facilities and offices across various states, while in Europe, it serves customers in countries like Germany, France, and the United Kingdom.
Danaher’s footprint extends to emerging markets in Asia-Pacific, including China, India, and Japan. It is also expanding its reach in Latin America, focusing on countries like Brazil and Mexico. Additionally, the company is in the Middle East and Africa, serving industries such as water quality, diagnostics, and life sciences.
Recent Developments
- In September 2023, Danaher Corporation announced its dedication to providing Cepheid’s Xpert MTB/RIF Ultra TB diagnostic test cartridges for $7.97 each to the Global Fund to Fight AIDS, TB, and Malaria, as well as to eligible less-developed countries through Cepheid’s Global Access Program. This effort aims to improve access to high-quality TB testing in these areas.
- In March 2023, Danaher Corporation disclosed a strategic collaboration with the University of Pennsylvania (Penn) to advance cell therapy innovation. This multi-year partnership seeks to create innovative technologies to enhance the reliability of clinical outcomes for patients and address production challenges in delivering advanced engineered cell products.
Agilent-Technologies
Company Overview
| Establishment Year | 1999 |
| Headquarter | Santa Clara, California, U.S. |
| Key Management | Mike McMullen (CEO) |
| Revenue (US$ Bn) | $ 6.8 Billion (2022) |
| Headcount | ~ 18,100 (2022) |
| Website | https://www.agilent.com/ |
About Agilent Technologies
Agilent Technologies, Inc. is a globally recognized company with a significant presence in microfluidics, particularly within the life sciences and analytical chemistry sectors. The company actively develops and provides microfluidic solutions, facilitating precise and efficient manipulation of small fluid volumes.
Agilent’s notable contributions in microfluidics encompass a portfolio of microfluidic instruments and systems that find critical applications in genomics, proteomics, and various life sciences endeavors. These technologies are pivotal in DNA sequencing, protein analysis, and drug discovery.
Geographical Presence
Agilent Technologies, Inc. maintains a global presence with headquarters in Santa Clara, California, serving North America, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. Their extensive network includes offices, manufacturing facilities, and research centers in key countries across these regions, supporting their diverse customer base spanning pharmaceuticals, biotechnology, environmental, food, and chemicals.
Recent Developments
- In October 2023, Agilent Technologies Inc. entered into an MOU with the SIDC, i.e., Sarawak Infectious Disease Centre in East Malaysia, which includes providing an Agilent 6475 triple quadrupole LC/MS system.
- In September 2023, Agilent Technologies Inc. inked a Research Collaboration Agreement (RCA) with the National Cancer Centre Singapore (NCCS) to expedite translational cancer research focused on the genomic characteristics of cancers prevalent in Asia.
Sphere-Fluidics
Company Overview
| Establishment Year | 2010 |
| Headquarter | Cambridge, UK |
| Key Management | Frank F. (CEO) |
| Revenue (US$ Bn) | $ 12.5 Million (2022) |
| Headcount | ~ 81 (2022) |
| Website | https://spherefluidics.com/ |
About Sphere Fluidics Limited
Sphere Fluidics Limited is a prominent company specializing in microfluidics, particularly known for its impactful contributions to life sciences, pharmaceuticals, and biotechnology. The company develops and provides microfluidic solutions that enable precise handling and analysis of small liquid volumes and particles.
Sphere Fluidics’ proprietary microfluidic technology platforms are instrumental in various applications, including cell sorting, single-cell analysis, and high-throughput screening. A significant aspect of their work is in single-cell analysis and encapsulation, allowing for the isolation and study of individual cells offering valuable insights into genomics, proteomics, and cell behavior.
Geographical Presence
Sphere Fluidics Limited is primarily based in the United Kingdom headquartered in Cambridge. While they have a significant presence in the UK, they also have offices, collaborators, or distributors in the United States, Europe, and Asia to serve the global biotech community.
Recent Developments
- In October 2023, Sphere Fluidics opened a cutting-edge facility at Granta Park in Cambridge, UK, to accommodate its R&D, sales, marketing, finance, human resources, commercial teams, and chemical manufacturing facilities.
- In June 2023, Sphere Fluidics revealed that Biosyntia, a biotech firm specializing in synthetic biology and metabolic engineering, has incorporated the Pico-Mine platform into its operations.
Discuss Your Needs With Our Analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
